NPPB and hydrops fetalis: Sacubitril/valsartan significantly lowered cardiovascular mortality, improved clinical outcomes (e.g., rehospitalization) and markedly reduced plasma NT-proBNP concentration, without major adverse events in acute decompensated HF, irrespective of the HF history or prior treatment with RAAS blockers [24,25].